KR20240119299A - 피라졸로[3,4-d]피리미딘 화합물의 고체 형태 - Google Patents
피라졸로[3,4-d]피리미딘 화합물의 고체 형태 Download PDFInfo
- Publication number
- KR20240119299A KR20240119299A KR1020247023041A KR20247023041A KR20240119299A KR 20240119299 A KR20240119299 A KR 20240119299A KR 1020247023041 A KR1020247023041 A KR 1020247023041A KR 20247023041 A KR20247023041 A KR 20247023041A KR 20240119299 A KR20240119299 A KR 20240119299A
- Authority
- KR
- South Korea
- Prior art keywords
- solid form
- approximately
- certain embodiments
- solid
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163290136P | 2021-12-16 | 2021-12-16 | |
| US63/290,136 | 2021-12-16 | ||
| PCT/US2022/081795 WO2023114995A1 (en) | 2021-12-16 | 2022-12-16 | Solid forms of pyrazolo[3,4-d]pyrimidine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240119299A true KR20240119299A (ko) | 2024-08-06 |
Family
ID=85172741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247023041A Pending KR20240119299A (ko) | 2021-12-16 | 2022-12-16 | 피라졸로[3,4-d]피리미딘 화합물의 고체 형태 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12012412B2 (https=) |
| EP (1) | EP4448529A1 (https=) |
| JP (1) | JP2024546844A (https=) |
| KR (1) | KR20240119299A (https=) |
| CN (1) | CN118401525A (https=) |
| AU (2) | AU2022416644B2 (https=) |
| CA (1) | CA3242577A1 (https=) |
| IL (1) | IL313314A (https=) |
| MX (1) | MX2024007517A (https=) |
| TW (1) | TW202333676A (https=) |
| WO (1) | WO2023114995A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12012412B2 (en) * | 2021-12-16 | 2024-06-18 | Pfizer Inc. | Solid forms of pyrazolo[3,4-d]pyrimidine compounds |
| AU2024329573A1 (en) * | 2023-08-22 | 2026-04-02 | Cardurion Pharmaceuticals, Inc. | Pyrazolo[3,4-d]pyrimidinone compounds for the treatment of chronic heart failure |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| RS52166B (sr) * | 2007-05-11 | 2012-08-31 | Pfizer Inc. | Amino-heterociklična jedinjenja |
| CN109893653A (zh) * | 2017-12-11 | 2019-06-18 | 王慧敏 | Pde9抑制剂的新用途 |
| US12012412B2 (en) | 2021-12-16 | 2024-06-18 | Pfizer Inc. | Solid forms of pyrazolo[3,4-d]pyrimidine compounds |
-
2022
- 2022-12-16 US US18/082,622 patent/US12012412B2/en active Active
- 2022-12-16 CN CN202280083751.7A patent/CN118401525A/zh active Pending
- 2022-12-16 AU AU2022416644A patent/AU2022416644B2/en active Active
- 2022-12-16 IL IL313314A patent/IL313314A/en unknown
- 2022-12-16 EP EP22854339.3A patent/EP4448529A1/en active Pending
- 2022-12-16 JP JP2024535383A patent/JP2024546844A/ja active Pending
- 2022-12-16 WO PCT/US2022/081795 patent/WO2023114995A1/en not_active Ceased
- 2022-12-16 MX MX2024007517A patent/MX2024007517A/es unknown
- 2022-12-16 TW TW111148528A patent/TW202333676A/zh unknown
- 2022-12-16 CA CA3242577A patent/CA3242577A1/en active Pending
- 2022-12-16 KR KR1020247023041A patent/KR20240119299A/ko active Pending
-
2024
- 2024-05-06 US US18/655,795 patent/US20240300961A1/en active Pending
-
2025
- 2025-12-03 AU AU2025275149A patent/AU2025275149A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024007517A (es) | 2024-08-19 |
| AU2022416644A1 (en) | 2024-07-04 |
| NZ812114A (en) | 2025-08-29 |
| AU2025275149A1 (en) | 2026-01-08 |
| CA3242577A1 (en) | 2023-06-22 |
| EP4448529A1 (en) | 2024-10-23 |
| TW202333676A (zh) | 2023-09-01 |
| CN118401525A (zh) | 2024-07-26 |
| IL313314A (en) | 2024-08-01 |
| JP2024546844A (ja) | 2024-12-26 |
| US12012412B2 (en) | 2024-06-18 |
| US20230192707A1 (en) | 2023-06-22 |
| WO2023114995A1 (en) | 2023-06-22 |
| AU2022416644B2 (en) | 2025-09-11 |
| US20240300961A1 (en) | 2024-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021530456A (ja) | ２−（３，５−ジクロロ−４−（（５−イソプロピル−６−オキソ−１，６−ジヒドロピリダジン−３−イル）オキシ）フェニル）−３，５−ジオキソ−２，３，４，５−テトラヒドロ−１，２，４−トリアジン−６−カルボニトリルの固体形態 | |
| US20240300961A1 (en) | Solid forms of pyrazolo[3,4-d]pyrimidine compounds | |
| EP4010322B1 (en) | Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof | |
| AU2022283638A1 (en) | Co-crystal forms of a novobiocin analog and proline | |
| KR20250144991A (ko) | Apj 수용체 활성을 갖는 화합물의 염 및 고체 형태 | |
| US20220251091A1 (en) | Amorphous umbralisib monotosylate | |
| US12559478B2 (en) | Co-crystal forms of selinexor | |
| US11136332B2 (en) | Morphic forms of marizomib and uses thereof | |
| US12030886B2 (en) | Form of ponatinib | |
| EA052651B1 (ru) | ТВЕРДЫЕ ФОРМЫ ПИРАЗОЛО[3,4-d]ПИРИМИДИНОВЫХ СОЕДИНЕНИЙ | |
| HK40112450A (zh) | 吡唑并[3，4-d]嘧啶化合物的固体形式 | |
| US20210246159A1 (en) | Novel form of bardoxolone methyl | |
| US11891401B2 (en) | Solid forms of N-(4-fluoro-3-(6-(3-methylpyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl)-2,4-dimethyloxazole-5-carboxamide | |
| WO2026024591A1 (en) | Tryptamine prodrug solid forms | |
| JP2023524622A (ja) | ６－クロロ－７－（４－（４－クロロベンジル）ピペラジン－１－イル）－２－（１，３－ジメチル－１Ｈ－ピラゾール－４－イル）－３Ｈ－イミダゾ［４，５－ｂ］ピリジンの塩及び多形体 | |
| WO2025137366A2 (en) | Solid-state forms of stat3 inhibitors and methods of use thereof | |
| EP4326737A1 (en) | Salts and crystalline forms of (3e) 3-[o-[(phosphonooxy)methyl]oxime]-pregn-4-ene-3, 20-dione and related uses | |
| HK40074778A (en) | Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof | |
| HK40074778B (en) | Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof | |
| WO2017120532A1 (en) | Polymorphs of a phosphate salt of quinuclidin-4-ylmethyl 4-methyl-1h-indole-3-carboxylate and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |